A nationwide cohort study on treatment and survival in patients with malignant peripheral nerve sheath tumours

Enrico Martin*, J Henk Coert, Uta E Flucke, Willem-Bart M Slooff, Vincent K Y Ho, Winette T van der Graaf, Thijs van Dalen, Michiel A J van de Sande, Winan J van Houdt, Dirk J Grünhagen, Cornelis Verhoef

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

53 Citations (Scopus)
14 Downloads (Pure)


BACKGROUND: Despite curative intents of treatment in localized malignant peripheral nerve sheath tumours (MPNSTs), prognosis remains poor. This study investigated survival and prognostic factors for overall survival in non-retroperitoneal and retroperitoneal MPNSTs in the Netherlands.

METHODS: Data were obtained from the Netherlands Cancer Registry and the Dutch Pathology Database. All primary MPNSTs were collected. Paediatric cases (age ≤18 years) and synchronous metastases were excluded from analyses. Separate Cox proportional hazard models were made for retroperitoneal and non-retroperitoneal MPNSTs.

RESULTS: A total of 629 localized adult MPNSTs (35 retroperitoneal cases, 5.5%) were included for analysis. In surgically resected patients (88.1%), radiotherapy and chemotherapy were administered in 44.2% and 6.7%, respectively. In retroperitoneal cases, significantly less radiotherapy and more chemotherapy were applied. In non-retroperitoneal MPNSTs, older age (60+), presence of NF1, size >5 cm, and deep-seated tumours were independently associated with worse survival. In retroperitoneal MPNSTs, male sex and age of 60+ years were independently associated with worse survival. Survival of R1 and that of R0 resections were similar for any location, whereas R2 resections were associated with worse outcomes. Radiotherapy and chemotherapy administrations were not associated with survival.

CONCLUSION: In localized MPNSTs, risk stratification for survival can be done using several patient- and tumour-specific characteristics. Resectability is the most important predictor for survival in MPNSTs. No difference is present between R1 and R0 resections in both retroperitoneal and non-retroperitoneal MPNSTs. The added value of radiotherapy and chemotherapy is unclear.

Original languageEnglish
Pages (from-to)77-87
Number of pages11
JournalEuropean Journal of Cancer
Early online date21 Nov 2019
Publication statusPublished - 1 Jan 2020

Bibliographical note

This research did not receive any specific grant from
funding agencies in the public, commercial, or not-forprofit sectors.

Copyright © 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Research programs

  • EMC OR-01


Dive into the research topics of 'A nationwide cohort study on treatment and survival in patients with malignant peripheral nerve sheath tumours'. Together they form a unique fingerprint.

Cite this